Skip To Main Content
Ad A.M. Masclee on Muck Rack

Ad A.M. Masclee

As seen in: Nature, Gastroenterology, Clinical Gastroenterology and Hepatology, Gastrointestinal Endoscopy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ad A.M.

Contact Ad A.M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Su1779 PHENOTYPING INCREASED URGE TO DEFECATE IN IRRITABLE BOWEL SYNDROME: ANALYSIS OF SYMPTOM, SENSORY, AND PSYCHOLOGICAL PROFILES

|
By Sylvester Raymond R. Groen, Lisa Vork, Jose M. Conchillo, Zsa Zsa R. Weerts, Zlatan Mujagic, Ad A.M. Masclee, Daisy M Jonkers, Daniel Keszthelyi
| Gastrointestinal Endoscopy Verified
Also available on ScienceDirect
Open in Who Shared Issue with article?

Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme - British Journal of Cancer

|
By Ad A.M. Masclee, Iris Lansdorp-Vogelaar, Tim L. Kortlever
| Nature Verified
Abstract Background Combining the faecal immunochemical test (FIT) result with risk factors for advanced neoplasia (AN) may increase the yield of colorectal cancer (CRC) screening without increasing the number of colonoscopies. We conducted a randomised controlled trial in the Dutch CRC screening programme to evaluate a previously developed risk model including FIT, age, sex, smoking status, and CRC family history.
Open in Who Shared Issue with article?

Discrete choice experiment reveals strong preference for dietary treatment among patients with irritable bowel syndrome

|
By CAPHRI Care, Daniel Keszthelyi, Ad A.M. Masclee, Rosel Sturkenboom
| Clinical Gastroenterology and Hepatology Verified
This paper is only available as a PDF. To read, Please Download here. Abstract Background & Aims Irritable Bowel Syndrome (IBS) is a highly prevalent, chronic disorder of the Gut-brain interaction which significantly affects quality of life. Several treatments, with comparable clinical efficacy, are available. Patient preferences can therefore be an important determinant of an effective management strategy. Treatment preferences of patients regarding decision-making remain unclear.
Open in Who Shared Issue with article?
See all 5 articles